March 27, 2017 09:08 AM EDT
R&D

A Foamix ac­ne drug PhI­II bombs, send­ing shares in­to a tail­spin

Arsalan Arif

Founder

While Al­ler­gan was pulling in­to the fi­nal reg­u­la­to­ry lap this morn­ing with its ex­per­i­men­tal ac­ne drug, ri­vals at Foamix tripped over a Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Sanofi dis­con­tin­ues De­nali-part­nered MS tri­al af­ter Phase 2 fail­ure

Lil­ly fol­lows the trend of new AI hires; Pfiz­er fills key UK po­si­tion as ac­tivist hub­bub swells

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Biotech star­tups Up­stream and CAMP4 price Fri­day IPOs

Up­dat­ed: FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

FDA ad­comm sup­ports first po­ten­tial drug for ul­tra-rare, fa­tal Barth syn­drome

A service from the Financial Times